Apnimed, Inc. APMD
17.80 USD +1.52 (+9.34%)
Regular-session close
17.80 0.00 0.00%
After hours · Nov 17, 4:01 PM ET
15.86 Day range 17.89
13.88 52-week range 35.29
- YTD
- -28.80%
- 1 year
- -28.80%
News
benzinga.com Apnimed Q3 EPS $(1.05) Misses $(0.59) Estimate, Sales $2.480M Down From $8.802M YoY Apnimed (NASDAQ:APMD) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.59) by 77.97 percent. This is a 42.62 percent increase over losses of $(1.83)…
globenewswire.com Apnimed Reports Third Quarter 2026 Financial Results and Provides Corporate Update New Drug Application (“NDA”) for AD109, with a proposed proprietary name Oxnimbi™ (aroxybutynin and atomoxetine) tablets, for oral use, remains under U.S. Food and Drug Administration (“FDA”) review…
seekingalpha.com Apnimed: Top Pick Biotech, Treating OSA With A Pill, Initiating With A Buy I initiate Apnimed with a 'Buy' rating and a $42 price target, citing mispriced FDA risk for Oxnimbi (AD109). Both Phase 3 trials met primary endpoints; NDA accepted with February 28, 2027 PDUFA…
